Combined General Meeting of June 3, 2026
Rhea-AI Summary
DBV Technologies (Nasdaq:DBVT) will hold its Combined General Meeting on June 3, 2026, at 10:00 a.m. CEST at its Châtillon headquarters. Shareholders can access the agenda, draft resolutions and voting instructions on the company website and request documents by email until May 29, 2026. The meeting will be webcast live, subject to technical conditions, and a replay will be posted within seven business days for at least the minimum required legal period.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – DBVT
On the day this news was published, DBVT gained 1.22%, reflecting a mild positive market reaction. This price movement added approximately $14M to the company's valuation, bringing the market cap to $1.16B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DBVT fell 1.77% while peers were mixed: CADL and NGNE up, OMER and CAPR down. With moves in both directions across peers, DBVT’s decline appears more stock-specific than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Q1 2026 earnings | Negative | -5.4% | Q1 2026 results with cash balance and net loss disclosure. |
| Apr 02 | Capital structure update | Neutral | -3.3% | Reported total shares and voting rights as of March 31, 2026. |
| Mar 26 | Annual report filing | Neutral | -1.0% | Filing of 2025 Form 10‑K and Universal Registration Document. |
| Mar 26 | FY 2025 earnings | Neutral | -1.0% | Full year 2025 financial results and business update on VIASKIN. |
| Mar 24 | Index inclusion | Positive | +3.7% | Admission to CAC Mid 60 and SBF 120 indices on March 23, 2026. |
Recent filings and earnings have often coincided with modest single‑digit moves, mostly negative, except for index inclusion, which saw a positive reaction.
Over the last few months, DBV Technologies has issued several corporate and regulatory updates. Earnings reports on March 26, 2026 and April 30, 2026 highlighted cash runway into Q2 2027 but were followed by single‑digit declines. Corporate notices on voting rights and filing of the 2025 10‑K and Universal Registration Document also saw modest negative moves. In contrast, inclusion in the CAC Mid 60 and SBF 120 indices on March 23, 2026 coincided with a positive reaction, underscoring index effects as a supportive catalyst.
Market Pulse Summary
This announcement outlines logistical details for DBV Technologies’ Combined General Meeting on June 3, 2026, including document access, deadlines, and webcast plans. It follows recent disclosures on cash runway, ownership structures, and index inclusion. Investors reviewing this information would typically focus on the agenda items, governance proposals, and any links to previously filed proxy materials, while also keeping prior earnings trends and capital structure changes in mind when interpreting the broader corporate context.
AI-generated analysis. Not financial advice.
Châtillon, France, May 13, 2026
Combined General Meeting of June 3, 2026
Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), will hold its Combined General Meeting (the “General Meeting”) on June 3, 2026, at 10:00 a.m. CEST (04:00 a.m. EST) at the Company’s headquarters located at IRO Building, 107 Avenue de la République, 92320 Châtillon, France.
The preliminary notice (avis de réunion) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for this General Meeting was published in the French “Bulletin des Annonces Légales Obligatoires (BALO)” dated April 29, 2026 (Bulletin 51, n° 2601207). The meeting notice (avis de convocation) was published today in the BALO (Bulletin 57, n° 2601701 ) and in the legal newspaper Les Affiches parisiennes.
The information and preparatory documents for this General Meeting are available to the Company's shareholders and are available on the Company's website (2026 Annual General Meeting | DBV Technologies), in accordance with the procedures and within the time limits provided for by the applicable legal and regulatory provisions.
This section will be updated regularly with all the necessary information.
Any shareholder wishing to receive these documents by email may make a request until midnight, Paris time, on May 29, 2026 (i.e., the fifth day before the General Meeting) by contacting the Company by post at the address of its headquarters or directly at the following email address: investors@dbv-technologies.com. For bearer shareholders, this request must be accompanied by a certificate of registration in the securities accounts held by an intermediary, in accordance with Article L. 211-3 of the French Monetary and Financial Code.
In accordance with the provisions of Article R. 225-88 of the French Commercial Code, the documents and information referred to in Articles R. 225-81 and R. 225-83 of the French Commercial Code have been made available on the Company’s website, so that the Company is exempt from sending them to the shareholders.
Webcast of the Annual General Meeting
The General Meeting will be webcast live on the Company's website, at the following address: 2026 Annual General Meeting | DBV Technologies, unless technical reasons prevent or materially disrupt such webcast.
The recorded webcast of the General Meeting will be disclosed no later than seven (7) business days after the date of the General Meeting and will remain accessible on the Company’s website for at least the minimum legal and regulatory period from its publication online.
About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of the VIASKIN Peanut Patch in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbvtechnologies.com and engage with us on X (formerly Twitter) and LinkedIn.
VIASKIN is a registered trademark of DBV Technologies.
Investor Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
